Time: February 2, 2017 from 1pm to 2pm
Location: Online Webinar - Eastern Time Zone
Website or Map: https://www.readytalk.com/join
Phone: 1.866.740.1260 -- Access code: 9449985
Event Type: webinar
Organized By: PPMD
Latest Activity: Feb 2, 2017
Thursday, February 2 at 1 PM ET
Yesterday the Duchenne community learned that Part B of the MoveDMD trial did not meet its primary endpoint, which was to demonstrate a statistically significant decrease in T2 MRI with edasalonexent after 12 weeks compared to placebo in people affected by Duchenne. There were some potential treatment-associated effects at 12 weeks in the 100 mg/kg/day treatment group when compared to placebo. Therefore, Catabasis will look to see if the signals strengthen in the longer-term data from the ongoing open-label extension.
The Catabasis team will speak to our community on Thursday, February 2 at 1 PM ET to discuss what they learned from this latest trial and what comes next in the MoveDMD program.
Please submit all questions to email@example.com (subject line: Catabasis Webinar) no later than 4 PM ET on Wednesday, February 1.
Please submit questions in advance to firstname.lastname@example.org, with “Catabasis Webinar” in the subject line by 4 PM ET on Wednesday, February 1.